![]() ![]() Roche’s 2022 net income was CHF 13.5 billion, down 10% compared to CHF 14.94 billion in 2021. The assays will be available on its Cobas fully automated analyzers.Įarlier in 2022, the firm developed a suite of tests to detect the monkeypox virus and in November, nabbed an FDA Emergency Use Authorization (EUA) for the polymerase chain reaction (PCR)-based Cobas MPXV monkeypox test for use on its fully automated, high-throughput platforms. Food and Drug Administration (FDA) clearance for the Elecsys AD CSF assays for the detection of Alzheimer’s disease. Implementing the study’s strategy in routine clinical practice has the potential to create a paradigm shift in the management of heart failure patients, Roche said. It was the first time a cardiac-related diagnostic study was stopped early because of superior efficacy in the active arm of the study. Roche said that among the most important milestones for the Diagnostics division in the fourth quarter of 2022, it shared positive outcomes of the STRONG-HF study, which leveraged its Elecsys NT-proBNP biomarker, in patients hospitalized with acute heart failure. Pathology Lab revenue growth across all regions was driven mainly by sales increases in the advanced staining and the companion diagnostics businesses. ![]() and Europe, was offset by a higher demand in emerging geographic markets. ![]() The continued contraction of the blood glucose monitoring market, mainly in the U.S. The decrease was partly offset by growth in the base business across the portfolio.ĭiabetes Care sales decreased because of the effect of the resolution of a rebate dispute in 2021. Molecular Lab revenues decreased in 2022 due to lower COVID-19-related sales in the North America and EMEA regions. Demand for the Cobas SARS-CoV-2 & Influenza A/B assays also increased, and the largest contribution came from the Asia-Pacific and North America regions, according to Roche. In the Point of Care business, SARS-CoV-2 Rapid Antigen tests continued to be the main growth driver. Sales grew across all regions but most growth was seen in the Asia-Pacific Europe, the Middle East, and Africa (EMEA) and Latin America regions. Uncover insights into our purpose-led journey focused on life-changing innovation, and see how our efforts to improve access to healthcare impacted millions of patients around the world.Immunoassays, such as cardiac and oncology tests, and clinical chemistry products were the main growth drivers in the Core Lab diagnostics segment. *Includes individuals from countries in Asia, Latin America, Eastern Europe, Middle East and Africa With the committing support for disability inclusion. ![]() In pay between men and women in similar jobs as our organisation-wide analysis confirmed Global D&I strategy focuses on four pillars: patient, people, culture, and society Inform Diagnostics is a leading anatomic pathology laboratory. Under-represented nationalities in executive positions*ĭiversity networks and chapters around the globe Your trusted laboratory services provider. Tests conducted with Roche Diagnostics products Will be screened for diabetes over the next two years in Meru, Kenya, through the Mwanga access project We continue to work with City Cancer Challenge, who are active in 13 cities worldwide reaching an estimated 59.6 million people HIV-positive patients were able to have their viral load monitored through the Global Access Program to check for treatment efficacy Worldwide in the Access to Medicine Index People were on Roche patient support programmes, a 14% increase from 2021 *Unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates (CER average rates 2021) and all total figures quoted are reported in CHF. We partner with stakeholders at global, country and community levels to enable access to innovative healthcare, no matter where people live. We put access at the core of our business and consider it a key part of our commitment to improving patient outcomes. Life-changing innovation is only meaningful if it reaches those who need it. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |